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Supplemental Figure 1. Cutaneous inflammation grading system. The magnitude of T cell 
immunity in the AK biopsies obtained one day after treatment completion is measured by the 
criteria used for skin graft rejection (1-3). Representative histological images of AKs that 
correspond to each grade are shown. 
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Supplemental Figure 2. CD8+ T cell accumulation and CD8+ TRM induction in AKs treated 
with calcipotriol plus 5-FU. Representative images of CD3/CD8/CD103-stained AKs on the face 
and scalp biopsied one day after treatment with calcipotriol plus 5-FU (C+F) or Vaseline plus 5-
FU (V+F) are shown (scale bar: 100 μm). 
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Supplemental Figure 3. CD4+ T and CD8+ T cell localization in AKs treated with calcipotriol 
plus 5-FU. (A) Representative images of CD4-stained or CD8-stained adjacent sections from an 
AK on the face treated with calcipotriol plus 5-FU combination are shown (arrows point to T cells 
contacting the premalignant keratinocytes, scale bar: 100 μm). Compared to CD4+ T cells, note 
the low density of CD8+ T cell infiltrates in the AK, which are mostly localized in the dermis and 
around the dermal blood vessels. (B) The number of CD4+ T cells contacting epidermal 
keratinocytes in AKs are compared after treatment with calcipotriol plus 5-FU (C+F) versus 
Vaseline plus 5-FU (V+F). (C) The number of CD8+ T cells contacting epidermal keratinocytes in 
AKs after calcipotriol plus 5-FU (C+F) versus Vaseline plus 5-FU (V+F) treatment are shown. (D) 
Bar graph shows the ratio of CD8+ T cells to CD4+ T cells contacting the AK keratinocytes in the 
test (C+F) and control (V+F) groups. The number of cells were counted across the length of the 
AK punch biopsy specimens obtained from face and scalp. The cell counts are presented per 1 
mm length of the epidermis (n = 3 per group, ns: not significant by Wilcoxon rank-sum test).  
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Supplemental Figure 4. Proportion of participants remaining free of SCC and BCC on any 
treated anatomical sites over time. Kaplan-Meier curves show the proportion of participants in 
the test and control group who remained (A) SCC and (B) BCC free on all their treated anatomical 
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sites during the >1500 days of follow-up after trial. 
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Supplemental Figure 5. Proportion of participants remaining BCC free on the treated face 
and scalp over time. Kaplan-Meier analysis shows the follow-up period of over >1500 days after 
trial. 
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Supplemental Figure 6. Differential immune microenvironments in BCC and SCC biopsied 
from the face of the same participant at a clinical visit after trial. H&E images depict the two 
KCs, a BCC and a SCC. Staining with CD3, CD4, CD8, and Foxp3 illustrates large T cell infiltrates 
in the SCC. In contrast, there is minimal T cell infiltrate at the periphery of the BCC, largely 
composed of immunosuppressive Foxp3+ regulatory T cells. Scale bars: 100μm. 
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Supplemental Figure 7. Differential immune microenvironments in BCC and AK-SCC 
spectrum lesions biopsied from the face and scalp of participants post-trial. KC biopsies 
from two participants in each treatment groups were stained for CD4+ and CD8+ T cells illustrating 
the magnitude of tumor infiltrating lymphocytes in BCCs compared to AK, SCCIS or SCC from 
the same participants. Each row represents KCs from a single participant. Scale bar: 100μm. 
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Supplemental Figure 8. TRM surface marker expression in epidermal T cells. Representative 
image of normal skin from a post-trial biopsy specimen that was collected from a participant in 
the calcipotriol plus 5-FU treatment group is shown with staining for CD3/CD4/CD69 and 
CD3/CD4/CD103  (dashed lines highlight the basement membrane, scale bar: 100 μm). 
  
Rosenberg et al., 2019 
 13 
Supplemental Table 1. Baseline demographic and clinical characteristics of participants 
treated on the face and scalp. 
 
  Calcipotriol + 5-FU Vaseline + 5-FU P value 
  (n=32) (n=40)  
     
Age, mean (SD), y 67 (7) 70 (8) 0.186 
(Range)  (56-81) (52-84)  
     
Gender, n (%)   0.451 
 Male 25 (78) 34 (85)  
 Female 7 (22) 6 (15)  
     
# Anatomical Sites Treated, n (%) 
 Face 26 (81) 34 (85) 0.671 
 Scalp 18 (56) 24 (60) 0.748 
     
Baseline AK Count on Each Anatomical Site, median (interquartile range) 
 Face 18 (11) 15 (12) 0.046 
 Scalp 23 (17) 21 (22) 0.565 
 RUE 13 (14) 17 (29) 0.354 
 LUE 12 (9) 11 (22) 0.797 
     
Skin Type, no. (%)  0.154 
 I 5 (16) 13 (33)  
 II 22 (69) 23 (58)  
 III 5 (16) 4 (10)  
     
Follow-up before trial, mean 
(SD), d 659 (477) 815 (382) 0.126 
(Range)  (8-1366) (24-1331)  
     
Follow-up after trial, mean 
(SD), d 1288 (200) 1255 (143) 0.403 
(Range)  (536-1531) (1016-1534)  
     
History of BCC before trial, n (%) 0.829 
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 0 20 (63) 24 (60)  
 >1 12 (38) 16 (40)  
     
History of SCC before trial, n (%) 0.826 
 0 20 (63) 26 (65)  
 >1 12 (38) 14 (35)  
     
History of KC before trial, n (%) 0.711 
 0 15 (47) 17 (43)  
 >1 17 (53) 23 (58)  
     
History of 5-FU treatment before trial, n (%) 0.203 
 0 23 (72) 23 (58)  
 >1 9 (28) 17 (43)  
     
History of PDT treatment before trial, n (%) 0.870 
 0 19 (59) 27 (68)  
 >1 13 (41) 13 (33)  
5-FU, 5-fluorouracil; RUE, right upper extremity; LUE, left upper extremity; AK, actinic keratosis; 














Rosenberg et al., 2019 
 15 
Supplemental Table 2. AK treatments that participants received after clinical trial. 
 
  Calcipotriol + 5-FU Vaseline + 5-FU P value 
  (n=41) (n=45)  
Frequency of cryotherapy on any location, mean (SD)  
  26 (24) 22 (21) 0.327 
     
5-FU monotherapy on any treated location, n (%)  
 0 23 (56) 23 (51) 0.643 
 >1 18 (44) 22 (49)  
     
5-FU monotherapy on treated face or scalp, n (%)  
 0 17 (53) 20 (50) 0.792 
 >1 15 (47) 20 (50)  
     
PDT on any treated location n (%)  0.614 
 0 29 (71) 34 (76)  
 >1 12 (29) 11 (24)  
     
PDT on treated face or scalp, n (%)   
 0 21 (66) 31 (78) 0.264 
 >1 11 (34) 9 (23)  
     
Field treatment on any treated location, n (%) 0.607 
 0 13 (32) 12 (27)  
 >1 28 (68) 33 (73)  
     
Field treatment on treated face or scalp, n (%) 0.556 
 0 10 (31) 10 (25)  
 >1 22 (69) 30 (75)  
5-FU, 5-fluorouracil. PDT, photodynamic therapy. 
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Supplemental Table 3. Cancer outcomes on all the treated anatomical sites. 
   




Participants With ≥1 
Lesion, n (%) 
Participants With 
≥1 Lesion, n (%) 
HR (95% CI) 
 
Year 1      
 KC 7 of 41 (17) 6 of 45 (13) 1.306 (0.439 - 3.886) 0.766 
 BCC 5 of 41 (12) 3 of 45 (7) 1.930 (0.461 - 8.075) 0.470 
 SCC 2 of 41 (5) 4 of 45 (9) 0.531 (0.097 - 2.897) 0.678 
      
Year 2      
 KC 12 of 40 (30) 12 of 45 (27) 1.034 (0.456 - 2.343) 1.000 
 BCC 8 of 40 (20) 5 of 45 (11) 1.921 (0.628 - 5.871) 0.367 
 SCC 5 of 40 (13) 9 of 45 (20) 0.577 (0.193 - 1.722) 0.395 
      
Year 3      
 KC 16 of 39 (41) 15 of 45 (33) 0.837  (0.384 - 1.822) 0.644 
 BCC 8 of 39 (21) 5 of 45 (11) 1.951 (0.638 - 5.965) 0.365 
 SCC 6 of 39 (15) 13 of 45 (29) 0.488  (0.186 - 1.285) 0.193 
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